Nestle to buy Aimmune, valuing allergy treatment maker at $2.6 billion

Nestle said on Thursday it was offering $34.50 per share for the remaining 74.4% in peanut allergy treatment maker Aimmune Therapeutics it does not already own as it adds what it hopes will be a lucrative treatment to its portfolio. The offer values the California-based biopharmaceutical company at $2.6 billion, including the $473 million that Nestle had already invested in Aimmune, Nestle said in a statement. The price represents a 174% premium to Aimmune's closing share price on August 28 of $12.60, said the food giant, which has been gearing its traditional portfolio towards health and wellness products.